کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5962826 1576127 2016 15 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients
چکیده انگلیسی


- Olmesartan as either monotherapy or combination therapy was more effective.
- Olmesartan was generally well tolerated compared to other antihypertensive agents.
- Olmesartan may be more cost-effective than other angiotensin receptor blockers.

The objective of the present study was to systematically review the clinical and economic outcomes of olmesartan as monotherapy or in combination with other antihypertensive agents in the treatment of hypertension. A literature search was performed using PubMed and the Cochrane library until December 2015, with no limit on publication date. Eligible studies were selected using predetermined inclusion and exclusion criteria, limiting articles to those published in the English language. Background information of the study, participants' characteristics and study outcomes were collected. Meta-analysis of data was not performed. Fifty-five studies were included, of which fifty investigated the clinical efficacy of olmesartan and five the cost-effectiveness of olmesartan. In general results from clinical trials evaluating the efficacy of olmesartan as monotherapy and as combination therapy demonstrated that olmesartan provided better antihypertensive blood pressure-lowering efficacy and was generally well tolerated compared with other antihypertensive agents. Results from economic evaluations indicated that olmesartan may be more cost-effective than other ARBs such as losartan, valsartan, irbesartan and candesartan, having the potential of decreasing the overall medical costs of care for patients with hypertension. Evidence from the present systematic review confirms the antihypertensive efficacy and good safety profile of olmesartan both as monotherapy and as combination therapy. Olmesartan was also found to be cost-effective compared with other ARBs, though this area has yet relatively poor evidence and needs to further be explored.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Cardiology - Volume 221, 15 October 2016, Pages 60-74
نویسندگان
, , , ,